Pharma R&D hides success of meds on some patients

06/18/2013 | New York Times (tiered subscription model), The

The pharmaceutical industry's research and development model conceals the positive effects of treatments on certain patients, writes New York Stem Cell Foundation CEO Susan L. Solomon in response to an article about patients left without drugs that helped them when a clinical trial ended. The use of stem cells to test efficacy in specific patients holds the promise of creating more targeted treatments for patients whose conditions can differ greatly, she writes.

View Full Article in:

New York Times (tiered subscription model), The